Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Gynecological: Ovarian

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

The purpose of this study is to evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase PFS relative to the standard / control regimen of cisplatin and radiation in women w/cancer

Status: Accepting New Patients
Principal Investigator: Shohreh Shahabi

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

To find out if the study drug INCB059872 is safe and may have beneficial effects in people who have different types of cancer.

Status: Accepting New Patients
Principal Investigator: Young Chae

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

The purpose of this study is to evaluate the efficacy either single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum sensitive ovarian, primary peritoneal or fallopian tube cancer.

Status: Accepting New Patients
Principal Investigator: Shohreh Shahabi

An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer

The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it takes for cancer to get worse when participants take the study drugs.

Status: Accepting New Patients
Principal Investigator: Daniela Matei

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

To determine the clinical activity of tivozanib in patients with platinum-resistant, recurrent ovarian, fallopian tube or primary peritoneal cancer.

Status: Accepting New Patients
Principal Investigator: Daniela Matei

Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with Or without Hippocampal Avoidance In Patients with Brain Metastases

To determine whether minimizing radiation dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation can decrease the risk of cognitive side effects after radiation therapy to the brain to using the usual whole-brain radiation plus memantine (a drug that can also reduce cognitive side effects of brain radiation).

Status: Accepting New Patients
Principal Investigator: Timothy Kruser

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Mon - October 16, 2017 - 04:30 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.